Thermo Fisher Scientific Inc.: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Nov 3, 2017 and accepted by EDGAR at Nov 3, 2017, 13:48 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2017-07-02 to 2017-09-30 | $2.17bn | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months2017-01-01 to 2017-09-30 | $6.55bn | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2017-07-02 to 2017-09-30 | $218.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-01-01 to 2017-09-30 | $655.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2017-07-02 to 2017-09-30 | $1.40bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2017-01-01 to 2017-09-30 | $4.02bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-07-02 to 2017-09-30 | $636.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-01-01 to 2017-09-30 | $2.01bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-07-02 to 2017-09-30 | $156.7m | us-gaap:InterestExpense |
| Interest expense | 9 months2017-01-01 to 2017-09-30 | $425.7m | us-gaap:InterestExpense |
| Income tax | 3 months2017-07-02 to 2017-09-30 | −$53.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-01-01 to 2017-09-30 | −$88.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-07-02 to 2017-09-30 | $533.9m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 9 months2017-01-01 to 2017-09-30 | $1.70bn | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2017-07-02 to 2017-09-30 | $1.34 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2017-01-01 to 2017-09-30 | $4.29 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-07-02 to 2017-09-30 | $1.35 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2017-01-01 to 2017-09-30 | $4.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-07-02 to 2017-09-30 | 399,600,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2017-01-01 to 2017-09-30 | 395,600,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2017-01-01 to 2017-09-30 | $2.14bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2017-01-01 to 2017-09-30 | $292.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2017-01-01 to 2017-09-30 | $177.1m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2017-01-01 to 2017-09-30 | $750.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-09-30 | $741.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $8.84bn | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $55.99bn | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $7.03bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | At period end2017-09-30 | $2.76bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2017-09-30 | $24.70bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2017-09-30 | 400,995,357 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000097745-17-000047. Last ingested by Listed: Nov 14, 2026, 12:05 ET. Listed shows no prices and gives no investment advice.